TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
AU2003265336B8
(en)
|
2002-07-29 |
2009-04-23 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
US7109337B2
(en)
*
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
GEP20084357B
(en)
|
2002-12-20 |
2008-04-29 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
PL1656372T3
(pl)
|
2003-07-30 |
2013-08-30 |
Rigel Pharmaceuticals Inc |
Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
|
BRPI0413616B8
(pt)
*
|
2003-08-15 |
2021-05-25 |
Irm Llc |
2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
JP2007505858A
(ja)
*
|
2003-09-18 |
2007-03-15 |
ノバルティス アクチエンゲゼルシャフト |
増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン
|
US7332521B2
(en)
*
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
CA2567574C
(en)
|
2004-04-08 |
2013-01-08 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
EP1756090A1
(en)
*
|
2004-05-14 |
2007-02-28 |
Pfizer Products Incorporated |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
GEP20104875B
(en)
*
|
2004-05-14 |
2010-01-11 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
BRPI0510963A
(pt)
*
|
2004-05-14 |
2007-11-20 |
Pfizer Prod Inc |
derivados pirimidina para o tratamento do crescimento anormal de células
|
WO2005111022A1
(en)
*
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Pyrimidines derivatives for the treatment of abnormal cell growth
|
WO2006024034A1
(en)
|
2004-08-25 |
2006-03-02 |
Targegen, Inc. |
Heterocyclic compounds and methods of use
|
DK1814878T3
(da)
|
2004-11-24 |
2012-05-07 |
Rigel Pharmaceuticals Inc |
Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
|
MX2007007189A
(es)
|
2005-01-19 |
2010-09-28 |
Rigel Pharmaceuticals Inc |
Prodrogas de compuestos de 2,4-pirimidindiamina y sus usos.
|
JP2008540391A
(ja)
*
|
2005-05-05 |
2008-11-20 |
アストラゼネカ アクチボラグ |
ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
|
PT1879573E
(pt)
|
2005-05-10 |
2013-03-25 |
Incyte Corp |
Moduladores de indoleamina 2,3-dioxigenase e métodos de utilização do mesmo
|
US20070032514A1
(en)
*
|
2005-07-01 |
2007-02-08 |
Zahn Stephan K |
2,4-diamino-pyrimidines as aurora inhibitors
|
EP1937667B1
(en)
*
|
2005-07-26 |
2010-10-13 |
Vertex Pharmaceuticals Incorporated |
Benzimidazoles useful as inhibitors of protein kinases
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
EP1966192B1
(en)
*
|
2005-12-01 |
2012-10-17 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
SI2348023T1
(sl)
|
2005-12-13 |
2015-10-30 |
Incyte Corporation |
S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
|
EP1966207A2
(en)
*
|
2005-12-21 |
2008-09-10 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
WO2007098418A1
(en)
*
|
2006-02-17 |
2007-08-30 |
Memory Pharmaceuticals Corporation |
Compounds having 5-ht6 receptor affinity
|
AR060061A1
(es)
*
|
2006-03-22 |
2008-05-21 |
Methylgene Inc |
Inhibidores de la actividad de la proteina tirosina quinasa
|
PE20080695A1
(es)
*
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
GEP20156282B
(en)
|
2006-12-08 |
2015-05-11 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
JP5492565B2
(ja)
|
2006-12-22 |
2014-05-14 |
インサイト・コーポレイション |
Janusキナーゼ阻害剤としての置換複素環
|
NZ601683A
(en)
*
|
2007-01-16 |
2012-11-30 |
Shionogi & Co |
Heterocyclic-substituted piperidine compounds for modulating ORL-1 receptor function in a cell
|
DE102007010801A1
(de)
|
2007-03-02 |
2008-09-04 |
Bayer Cropscience Ag |
Diaminopyrimidine als Fungizide
|
CN101678215B
(zh)
|
2007-04-18 |
2014-10-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的磺酰胺衍生物
|
KR101294731B1
(ko)
*
|
2007-06-04 |
2013-08-16 |
삼성디스플레이 주식회사 |
어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
|
CU24179B1
(es)
|
2007-06-13 |
2016-04-25 |
Incyte Corp |
SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
KR20100049068A
(ko)
|
2007-07-17 |
2010-05-11 |
리겔 파마슈티칼스, 인크. |
Pkc 억제제로서의 시클릭 아민 치환된 피리미딘디아민
|
WO2009023844A2
(en)
*
|
2007-08-15 |
2009-02-19 |
Memory Pharmaceuticals Corporation |
3' substituted compounds having 5-ht6 receptor affinity
|
NZ582940A
(en)
|
2007-08-31 |
2013-01-25 |
Purdue Pharma Lp |
Substituted-quinoxaline-type piperidine compounds and the uses thereof
|
JPWO2009054332A1
(ja)
*
|
2007-10-23 |
2011-03-03 |
萬有製薬株式会社 |
ピリドン置換ジヒドロピラゾロピリミジノン誘導体
|
BRPI0820544A2
(pt)
|
2007-11-16 |
2015-06-16 |
Incyte Corp |
4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
|
CA2707653A1
(en)
*
|
2007-12-03 |
2009-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
BRPI0909040B8
(pt)
|
2008-03-11 |
2021-05-25 |
Incyte Holdings Corp |
derivados de azetidina e ciclobutano, seus usos, e composição
|
KR101238585B1
(ko)
*
|
2008-04-07 |
2013-02-28 |
노파르티스 아게 |
단백질 키나제 억제제로서의 화합물 및 조성물
|
US8871753B2
(en)
|
2008-04-24 |
2014-10-28 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
US20100016297A1
(en)
*
|
2008-06-24 |
2010-01-21 |
Memory Pharmaceuticals Corporation |
Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3549934A1
(en)
|
2008-06-27 |
2019-10-09 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US20100022581A1
(en)
*
|
2008-07-02 |
2010-01-28 |
Memory Pharmaceuticals Corporation |
Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
|
RS53688B9
(sr)
|
2008-07-08 |
2020-01-31 |
Incyte Holdings Corp |
1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
|
US20100029629A1
(en)
*
|
2008-07-25 |
2010-02-04 |
Memory Pharmaceuticals Corporation |
Acyclic compounds having 5-ht6 receptor affinity
|
US20100056531A1
(en)
*
|
2008-08-22 |
2010-03-04 |
Memory Pharmaceuticals Corporation |
Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
JP5781943B2
(ja)
*
|
2009-01-21 |
2015-09-24 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なn2−(3−ピリジルまたはフェニル)−n4−(4−ピペリジル)−2,4−ピリミジンジアミン誘導体
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
JP2010111702A
(ja)
|
2009-02-16 |
2010-05-20 |
Tetsuya Nishio |
複素環化合物、その製造法および用途
|
WO2010129053A2
(en)
|
2009-05-05 |
2010-11-11 |
Dana Farber Cancer Institute |
Egfr inhibitors and methods of treating disorders
|
US8716303B2
(en)
|
2009-05-22 |
2014-05-06 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
HUE046493T2
(hu)
|
2009-05-22 |
2020-03-30 |
Incyte Holdings Corp |
3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
RS53494B9
(sr)
|
2009-06-29 |
2020-11-30 |
Incyte Holdings Corp |
Pirimidinoni kao inhibitori pi3k
|
US8933227B2
(en)
|
2009-08-14 |
2015-01-13 |
Boehringer Ingelheim International Gmbh |
Selective synthesis of functionalized pyrimidines
|
JP5539518B2
(ja)
|
2009-08-14 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
PT2486041E
(pt)
|
2009-10-09 |
2013-11-14 |
Incyte Corp |
Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
WO2011075630A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
|
JP5858434B2
(ja)
|
2010-02-18 |
2016-02-10 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Janusキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
|
DK3050882T3
(en)
|
2010-03-10 |
2018-03-19 |
Incyte Holdings Corp |
PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
US8927547B2
(en)
*
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
EP2395001A1
(en)
*
|
2010-05-21 |
2011-12-14 |
Chemilia AB |
Novel pyrimidine derivatives
|
ME02445B
(me)
|
2010-05-21 |
2016-09-20 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
US10010439B2
(en)
|
2010-06-13 |
2018-07-03 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
US9526648B2
(en)
|
2010-06-13 |
2016-12-27 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
US8628554B2
(en)
|
2010-06-13 |
2014-01-14 |
Virender K. Sharma |
Intragastric device for treating obesity
|
US10420665B2
(en)
|
2010-06-13 |
2019-09-24 |
W. L. Gore & Associates, Inc. |
Intragastric device for treating obesity
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
BR112013003388A2
(pt)
|
2010-08-10 |
2016-07-12 |
Celgene Avilomics Res Inc |
sal de besilato de um inibidor de btk
|
DE102010034699A1
(de)
*
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
TWI632134B
(zh)
|
2010-11-01 |
2018-08-11 |
阿維拉製藥公司 |
雜環化合物及其用途
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
UA113156C2
(xx)
|
2010-11-19 |
2016-12-26 |
|
Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
WO2012074951A1
(en)
|
2010-11-29 |
2012-06-07 |
OSI Pharmaceuticals, LLC |
Macrocyclic kinase inhibitors
|
AR084366A1
(es)
|
2010-12-20 |
2013-05-08 |
Incyte Corp |
N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
|
US8546443B2
(en)
*
|
2010-12-21 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Benzylic oxindole pyrimidines
|
CN103534241B
(zh)
|
2011-02-17 |
2015-11-25 |
癌症疗法Crc私人有限公司 |
Fak抑制剂
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
JP5936628B2
(ja)
|
2011-02-18 |
2016-06-22 |
ノバルティス・ファルマ・アクチェンゲゼルシャフトNovartis Pharma AG |
mTOR/JAK阻害剤併用療法
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
CA2830129C
(en)
|
2011-03-24 |
2016-07-19 |
Chemilia Ab |
Novel pyrimidine derivatives
|
EP2502924A1
(en)
|
2011-03-24 |
2012-09-26 |
Chemilia AB |
Novel pyrimidine derivatives
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
CN103649074B
(zh)
*
|
2011-07-07 |
2016-05-11 |
默克专利股份公司 |
用于治疗癌症的取代的氮杂环
|
WO2013023119A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
JAK P13K/mTOR COMBINATION THERAPY
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
HUE043703T2
(hu)
|
2011-09-02 |
2019-09-30 |
Incyte Holdings Corp |
Heterociklusos aminok PI3K inhibitorokként
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
WO2013063401A1
(en)
|
2011-10-28 |
2013-05-02 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
CA2850594C
(en)
*
|
2011-11-29 |
2020-03-10 |
F. Hoffmann-La Roche Ag |
Aminopyrimidine derivatives as lrrk2 modulators
|
AU2012357038B2
(en)
|
2011-12-23 |
2016-05-12 |
Cellzome Limited |
Pyrimidine-2,4-diamine derivatives as kinase inhibitors
|
US9056839B2
(en)
|
2012-03-15 |
2015-06-16 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
SI2825042T1
(sl)
|
2012-03-15 |
2019-01-31 |
Celgene Car Llc |
Soli inhibitorja kinaze receptorja faktorja epidermalne rasti
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
RS55908B1
(sr)
|
2012-06-13 |
2017-09-29 |
Incyte Holdings Corp |
Substituisana triciklična jedinjenja kao inhibitori fgfr
|
EP2711365A1
(en)
|
2012-09-21 |
2014-03-26 |
Chemilia AB |
4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
|
EP2711364A1
(en)
|
2012-09-21 |
2014-03-26 |
Chemilia AB |
4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
|
SG10201703533VA
(en)
|
2012-11-01 |
2017-06-29 |
Incyte Corp |
Tricyclic fused thiophene derivatives as jak inhibitors
|
PE20151157A1
(es)
|
2012-11-15 |
2015-08-19 |
Incyte Corp |
Formas de dosificacion de ruxolitinib de liberacion sostenida
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
CA2900012A1
(en)
|
2013-02-08 |
2014-08-14 |
Celgene Avilomics Research, Inc. |
Erk inhibitors and uses thereof
|
TWI736135B
(zh)
|
2013-03-01 |
2021-08-11 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
PE20151902A1
(es)
|
2013-03-06 |
2015-12-26 |
Incyte Corp |
Proceso e intermedios para hacer un inhibidor de jak
|
MX367878B
(es)
|
2013-04-19 |
2019-09-10 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
|
EP4275756A3
(en)
|
2013-05-17 |
2024-02-07 |
Incyte Holdings Corporation |
Bipyrazole derivatives as jak inhibitors
|
RS60469B1
(sr)
|
2013-08-07 |
2020-07-31 |
Incyte Corp |
Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
|
MX2016002165A
(es)
|
2013-08-20 |
2017-01-05 |
Incyte Corp |
Beneficio de supervivencia en pacientes con tumores solidos con niveles elevados de proteina c reactiva.
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
SI3110409T1
(sl)
|
2014-02-28 |
2018-11-30 |
Incyte Corporation |
Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
|
MA54622A
(fr)
|
2014-04-08 |
2021-11-03 |
Incyte Corp |
Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
|
SG11201609016VA
(en)
|
2014-04-30 |
2016-11-29 |
Incyte Corp |
Processes of preparing a jak1 inhibitor and new forms thereto
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
DK3179858T3
(da)
|
2014-08-13 |
2019-07-22 |
Celgene Car Llc |
Forme og sammensætninger af en ERK-inhibitor
|
EP4070795A1
(en)
|
2014-08-25 |
2022-10-12 |
Salk Institute for Biological Studies |
Novel ulk1 inhibitors and methods using same
|
WO2016130501A1
(en)
|
2015-02-09 |
2016-08-18 |
Incyte Corporation |
Aza-heteroaryl compounds as pi3k-gamma inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
ES2751669T3
(es)
|
2015-02-20 |
2020-04-01 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores FGFR
|
PL3262046T3
(pl)
|
2015-02-27 |
2021-05-04 |
Incyte Corporation |
Sole inhibitora pi3k i sposoby ich wytwarzania
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183062A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
KR20180100539A
(ko)
|
2015-06-29 |
2018-09-11 |
베라스템, 인코포레이티드 |
치료용 조성물, 병용 및 적용과 관련된 사용방법
|
HUE059324T2
(hu)
|
2015-11-06 |
2022-11-28 |
Incyte Corp |
Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
|
AR107293A1
(es)
|
2016-01-05 |
2018-04-18 |
Incyte Corp |
COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
|
US10779980B2
(en)
|
2016-04-27 |
2020-09-22 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
SI3697789T1
(sl)
|
2017-10-18 |
2022-04-29 |
Incyte Corporation |
Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019126505A1
(en)
|
2017-12-21 |
2019-06-27 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
|
MA51771B1
(fr)
|
2018-01-30 |
2022-03-31 |
Incyte Corp |
Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
|
BR112020016628A2
(pt)
|
2018-02-16 |
2020-12-15 |
Incyte Corporation |
Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
|
CN112384515A
(zh)
|
2018-02-27 |
2021-02-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
|
CR20240101A
(es)
|
2018-03-08 |
2024-05-24 |
Incyte Corp |
COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464)
|
BR112020018585A8
(pt)
|
2018-03-12 |
2022-12-06 |
Inst Nat Sante Rech Med |
Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer
|
CN112423759A
(zh)
|
2018-03-30 |
2021-02-26 |
因赛特公司 |
使用jak抑制剂治疗化脓性汗腺炎
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
AU2019262195B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Solid forms of an FGFR inhibitor and processes for preparing the same
|
CA3100731A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
MA52754A
(fr)
|
2018-05-25 |
2021-04-14 |
Incyte Corp |
Composés hétérocycliques tricycliques en tant qu'activateurs de sting
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
US11161850B2
(en)
|
2018-07-05 |
2021-11-02 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
WO2020028565A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Tricyclic heteraryl compounds as sting activators
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
RS65334B1
(sr)
|
2018-09-05 |
2024-04-30 |
Incyte Corp |
Kristalni oblici inhibitora fosfatidilinozitol 3-kinaze (pi3k)
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
CN114040764A
(zh)
|
2019-02-15 |
2022-02-11 |
因赛特公司 |
细胞周期素依赖性激酶2生物标记物及其用途
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
AU2020290995A1
(en)
|
2019-06-10 |
2022-04-07 |
Incyte Corporation |
Topical treatment of vitiligo by a JAK inhibitor
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
CR20220066A
(es)
|
2019-08-14 |
2022-11-28 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
BR112022003408A2
(pt)
|
2019-08-26 |
2022-05-17 |
Incyte Corp |
Triazolopirimidinas como inibidores de a2a/a2b
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
CN115835908A
(zh)
|
2019-10-14 |
2023-03-21 |
因赛特公司 |
作为fgfr抑制剂的双环杂环
|
US11992490B2
(en)
|
2019-10-16 |
2024-05-28 |
Incyte Corporation |
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
|
WO2021076124A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
JP2023505258A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式複素環
|
US11407750B2
(en)
|
2019-12-04 |
2022-08-09 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
WO2021211864A1
(en)
|
2020-04-16 |
2021-10-21 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
CA3184275A1
(en)
|
2020-06-02 |
2021-12-09 |
Incyte Corporation |
Processes of preparing a jak1 inhibitor
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
EP4213800A1
(en)
|
2020-09-16 |
2023-07-26 |
Incyte Corporation |
Topical treatment of vitiligo
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
TW202237089A
(zh)
|
2020-12-08 |
2022-10-01 |
美商英塞特公司 |
用於治療白斑病之jak1途徑抑制劑
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
CN116348117A
(zh)
*
|
2021-03-23 |
2023-06-27 |
杭州阿诺生物医药科技有限公司 |
Hpk1激酶抑制剂化合物
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
CA3215903A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
IL309642A
(en)
|
2021-07-07 |
2024-02-01 |
Incyte Corp |
Tricyclic compounds as inhibitors of Kras
|
JP2024529347A
(ja)
|
2021-07-14 |
2024-08-06 |
インサイト・コーポレイション |
Krasの阻害剤としての三環式化合物
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
WO2023091746A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
US20230203010A1
(en)
|
2021-12-03 |
2023-06-29 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
IL313735A
(en)
|
2021-12-22 |
2024-08-01 |
Incyte Corp |
Salts and solid forms of Pajfer inhibitor and processes for their preparation
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2抑制劑及其用途
|
AR128717A1
(es)
|
2022-03-07 |
2024-06-05 |
Incyte Corp |
Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
|
US20230399331A1
(en)
|
2022-06-14 |
2023-12-14 |
Incyte Corporation |
Solid forms of jak inhibitor and process of preparing the same
|
TW202413359A
(zh)
|
2022-06-22 |
2024-04-01 |
美商英塞特公司 |
雙環胺cdk12抑制劑
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
US20240058343A1
(en)
|
2022-08-05 |
2024-02-22 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|